Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis

R Rompel1, C Garbe, P Büttner

  • 1Department of Dermatology, Municipal Clinics of Kassel, Germany.

Melanoma Research
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same journal

Dissecting cellular heterogeneity across two ocular melanoma subtypes by single-cell RNA sequencing.

Melanoma research·2026
Same journal

An online cutaneous melanoma risk screen tool.

Melanoma research·2026
Same journal

The role of circulating tumor DNA in the management of melanoma: a literature review.

Melanoma research·2026
Same journal

Schisandrin C suppresses melanoma growth and metastasis through modulation of Rap1-related and phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin signaling pathways.

Melanoma research·2026
Same journal

Factors to consider in a primary care setting when using convolutional neural network tools for melanoma diagnostics: a retrospective analysis of images and patient characteristics.

Melanoma research·2026
Same journal

Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB-IIC melanoma.

Melanoma research·2026
See all related articles

Elective lymph node dissection (ELND) shows survival benefits for trunk malignant melanoma. It also improves disease-free survival for intermediate tumor thicknesses, suggesting its value in improving prognosis.

Area of Science:

  • Oncology
  • Surgical Oncology

Background:

  • The role of elective lymph node dissection (ELND) in primary malignant melanoma management remains debated.
  • Wide local excision (WLE) is standard, but the added benefit of ELND requires further evaluation.

Purpose of the Study:

  • To assess the impact of ELND on survival and disease-free survival in patients with malignant melanoma of the trunk and extremities.
  • To determine if ELND offers advantages over WLE alone based on tumor characteristics.

Main Methods:

  • A matched-pair analysis was conducted on a cohort of 750 patients with primary malignant melanoma.
  • Outcomes were compared between patients treated with WLE plus ELND and those treated with WLE alone.

Main Results:

  • No significant overall survival benefit was observed for WLE plus ELND compared to WLE alone in the total patient group.

Related Experiment Videos

  • However, ELND demonstrated a significant benefit for malignant melanoma of the trunk (p < 0.05).
  • Disease-free survival rates were significantly higher with ELND for all tumor thicknesses (p < 0.05), particularly for intermediate thicknesses (1.51-4.0 mm, p < 0.001).

    • Conclusions:

    • Elective lymph node dissection may be beneficial for improving prognosis in malignant melanoma, especially for tumors with intermediate Breslow thickness.
    • ELND shows a significant survival advantage for trunk melanomas and improved disease-free survival across various tumor depths.